Aurobindo Pharma announced of receiving an Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from USFDA for its Hyderabad facility.

Bandhan Bank’s current promoter holding is still above the mandated level, that is, at 61 per cent, however, despite this, RBI removed its restriction on the pretext of ‘considering the efforts made by Bandhan Bank to comply with the said licensing condition.’

Pharma major Cipla reported to the exchanges that United States Food and Drug Administration (USFDA) have issued a warning letter in accordance with the inspection held at the company’s manufacturing facility in Goa.

Overall, the structure is weak for the short-term and rallies are likely to be sold until the resistance zone of 11,900-11,930 is not crossed. Stocks in news: IRB Infrastructure Developers, Bandhan Bank, Bank of Baroda, Godawari Power & Ispat, Arrow Greentech.

The colossal sell-off overnight on Wall Street as Centres for Disease Control (CDC) officials called the spread of Coronavirus in United States inevitable and this has triggered a negative sentiment in Asian markets as well. Early action at SGX Nifty is indicating a worrisome sign ahead for Indian markets as there are chances that we might open with a big gap down.

Besides, an official statement issued by Sanjay Gupta, Company Secretary & Chief Compliance Officer at InterGlobe Aviation states that the report is factually incorrect and the company has not received any communication from SEBI in this regard.

Lupin announced the launch of Ethacrynic Acid Tablets USP, 25 mg used for the treatment of Edema. The pharma major had already received an approval from United States Food and Drug Administration (USFDA) earlier for this drug.

Fixed deposits are one of the most popular fixed income investments among retail investors. Having said that, what are the checks that investors should perform before investing in bank FDs? Let’s find out!

On Tuesday, the stock has given a neckline breakout of triple bottom pattern. This breakout was confirmed by above 50-day average volumes. 

The capex and project will be executed through its wholly-owned subsidiary, Navin Fluorine Advanced Sciences Limited (NFASL). It will invest around USD 51.5 million for setting up dedicated manufacturing facility and USD 10 million for setting up captive power plant.